BARDA Awards Vericel 10-Year Contract Worth Up to $197 Million for NexoBrid Procurement and Development

Overview

• Vericel said the U.S. Biomedical Advanced Research and Development Authority awarded a ten-year contract worth up to $197 million for NexoBrid.
• The base period totals $35 million with about $10 million set for initial purchases for the U.S. Strategic National Stockpile and for starting a vendor-managed inventory program run by the company.
• The agreement includes options for more procurement plus funding for a potential blast-trauma use, design and validation of a U.S. manufacturing site, and a room‑temperature stable formulation.
• NexoBrid removes dead burn tissue without surgery and is cleared in the United States for adults and children, with Vericel holding exclusive North American rights.
• BARDA, part of HHS’s preparedness arm, is funding the program under contract 75A50126C00002 to strengthen the national response to large burn or blast incidents.